Hepatitis B News and Research

Latest Hepatitis B News and Research

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

El Camino Hospital introduces CHI program to educate Chinese community on health disparities

El Camino Hospital has launched a Chinese Health Initiative, designed to address the troubling and unique health disparities in the Silicon Valley's Chinese community and to accommodate their cultural preferences in education, screening and health care delivery.

19 Jan 2011

Transplant surgeons routinely use fewer organs from high-risk donors

As a response to a 2007 episode in which four patients in Chicago were transplanted with organs from a single donor unknowingly infected with HIV — the only such episode in 20 years — one-third of transplant surgeons in the United States "overreacted" and began routinely using fewer organs from high-risk donors, new research from Johns Hopkins finds.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Two multinational clinical studies indicate that the RDI’s system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.

18 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Transplanting their own bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation. Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.

11 Jan 2011

Medical aid workers should take pre-travel precautions to prevent disease transmission

Guidance about pre-travel precautions and preventive measures are highlighted in the December 1, 2010 issue of Clinical Infectious Diseases, written by clinicians and researchers at the Uniformed Services University of the Health Sciences and their partners from the University of Texas Health Sciences Center, Naval Medical Research Center and others.

11 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

New lab-on-a-chip technology detects protein in blood less than 30 minutes

While most blood tests require shipping a vial of blood to a laboratory for analysis and waiting several days for the results, a new device invented by a team of engineers and students at the University of Rhode Island uses just a pinprick of blood in a portable device that provides results in less than 30 minutes.

10 Jan 2011

FDA, EMA accept boceprevir for expedited review

Merck, known as MSD outside the United States and Canada, announced today that regulatory applications for boceprevir, Merck's investigational oral hepatitis C virus (HCV) protease inhibitor, were submitted in 2010 and have been accepted for expedited review in both the U.S. and the European Union.

10 Jan 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Dongsheng Pharmaceutical International Co., Ltd. announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co. I.

5 Jan 2011

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.

4 Jan 2011

Hepatitis A scare at Long Island church

Health officials have warned that parishioners who received Holy Communion during Christmas Mass at a church on Long Island may have been exposed to hepatitis A and may need vaccinated as soon as possible. Particularly those who received Communion at the 10.30am and 12pm (local time) masses on December 25, 2010, at Our Lady of Lourdes Church in Massapequa Park should get the shots.

4 Jan 2011

Hepatitis B News and Research

Latest Hepatitis B News and Research

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

El Camino Hospital introduces CHI program to educate Chinese community on health disparities

Transplant surgeons routinely use fewer organs from high-risk donors

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Medical aid workers should take pre-travel precautions to prevent disease transmission

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

New lab-on-a-chip technology detects protein in blood less than 30 minutes

FDA, EMA accept boceprevir for expedited review

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Scientists identify prognostic biomarker to treat patients with HCV

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Anadys begins ANA598 Phase IIb study for hepatitis C

Hepatitis A scare at Long Island church

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis B News and Research

Latest Hepatitis B News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in